Clinical trials
Recent articles
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Explore more from The Transmitter
After the ‘Thank you’ slide: When lived trauma enters trauma neuroscience
Trauma researchers need professional norms that allow brief, humane acknowledgment when acute trauma directly affects a scientific community.
After the ‘Thank you’ slide: When lived trauma enters trauma neuroscience
Trauma researchers need professional norms that allow brief, humane acknowledgment when acute trauma directly affects a scientific community.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Separate neuronal pathways mediate social, attentional behaviors
Here is a roundup of autism-related news and research spotted around the web for the week of 20 July.
Separate neuronal pathways mediate social, attentional behaviors
Here is a roundup of autism-related news and research spotted around the web for the week of 20 July.